BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15452399)

  • 1. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.
    Drago L; De Vecchi E; Nicola L; Colombo A; Guerra A; Gismondo MR
    Chemotherapy; 2004 Oct; 50(4):202-10. PubMed ID: 15452399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.
    Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
    J Antimicrob Chemother; 2005 Aug; 56(2):353-9. PubMed ID: 15967767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pseudomonas aeruginosa: bactericidal activity on various beta-lactam resistance phenotypes of 8 antibiotics and 7 combinations].
    Dubrous P; Cavallo JD; Hernandez E; Nordmann P; Fabre R
    Pathol Biol (Paris); 1997 May; 45(5):433-7. PubMed ID: 9296099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp.
    Sader HS; Jones RN
    Int J Antimicrob Agents; 2005 May; 25(5):380-4. PubMed ID: 15848291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
    Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
    Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
    J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
    Wang H; Chen MJ;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [E-test to study small inhibitor concentrations, bacterial diversity and to identify presumptively beta-lactamases in strains of Pseudomonas aeruginosa and Acinetobacter baumannii associated with +nosocomial infections].
    Triantafilo V; Fica A; Silva M; Thompson L
    Rev Med Chil; 1997 Feb; 125(2):149-60. PubMed ID: 9430934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Pfaller MA; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of antibiotic resistance patterns of Pseudomonas aeruginosa and Acinetobacter spp. strains isolated from intensive care patients between 2000-2002 and 2003-2006 periods in Dokuz Eylul University Hospital, Izmir].
    Yüce A; Yapar N; Eren Kutsoylu O
    Mikrobiyol Bul; 2009 Apr; 43(2):195-202. PubMed ID: 19621603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
    Unal S; Garcia-Rodriguez JA
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains.
    Kádár B; Szász M; Kristóf K; Pesti N; Krizsán G; Szentandrássy J; Rókusz L; Nagy K; Szabó D
    Acta Microbiol Immunol Hung; 2010 Sep; 57(3):235-45. PubMed ID: 20870595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and changing minimum inhibitory concentration (MIC) of Acinetobacter species from a tertiary care setup.
    Capoor MR; Nair D; Srivastava L; Gupta B; Aggarwal P
    J Commun Dis; 2005 Jun; 37(2):99-107. PubMed ID: 16749272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.
    Chen YH; Peng CF; Lu PL; Tsai JJ; Chen TP
    Kaohsiung J Med Sci; 2004 Jun; 20(6):261-7. PubMed ID: 15253466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
    Pankey GA; Ashcraft DS
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2959-64. PubMed ID: 15980375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
    Burgess DS; Nathisuwan S
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):35-41. PubMed ID: 12376029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
    Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
    Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa.
    Oie S; Uematsu T; Sawa A; Mizuno H; Tomita M; Ishida S; Okano Y; Kamiya A
    J Antimicrob Chemother; 2003 Dec; 52(6):911-4. PubMed ID: 14585851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or beta-lactams against extended-spectrum beta-lactamase-producing Escherichia coli.
    Drago L; De Vecchi E; Nicola L; Legnani D; Lombardi A; Gismondo MR
    J Chemother; 2005 Feb; 17(1):46-53. PubMed ID: 15828443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.